Bala Vanessa Meletia Internist Oncologist

Board Member

Member of ESMO, Hellenic Society of Medical Oncology (HESMO) and the Hellenic Cooperative Oncology Group (HeCOG)

Professional Experience

· 03.2023 – today Medical Oncologist YGEIA & MITERA Hospital

· 12.2022 – 03.2023 Medical Oncologist, Euroclinic, Athens, Greece

· 02.2020 – 12.2022 Resident Doctor in Medical Oncology, 2nd Department of Medical Oncology, General Oncologica11Hospital of Kifissia

· 11.2018 – 02.2020 Resident Doctor, Oncology Department, General Hospital of Athens “G.Gennimatas”

· 11.2017-11.2018 Resident Doctor in Hematology, General Hospital of Athens “G.Gennimatas”

· 11.2013-11.2015 Resident Doctor in Internal Medicine, 1st Department of Internal Medicine, General Hospital of Athens “G.Gennimatas”

· Resident doctor in Medical Oncology, Department of Oncology and Cellular Therapy, Hôpital Tenon AP-HP, Paris, 05.2015-11.2015 and Pneumonology and Oncology Department, Centre Hospitalier Saint Germain En Laye, Paris, France, 11.2013 – 05.2013

· 05.2014 – 05.2015 Resident doctor in Internal Medicine, Department of Internal Medicine, Centre Hospitalier Saint Germain En Laye, Paris, France and Department of Internal Medicine, Centre Hospitalier d’Orsay, Paris, France

· 02.2013 – 10.2013 Research Assistant, Oncology Unit, General Hospital of Athens Ippokrateio

Education Experience

· Presentations at numerous congresses

· Active member of the General Medicine training program of the Université de Versailles, with responsibility for coordinating and conducting speeches and councils.

Clinical and Research Interest

· Gynaecological cancer

· Urogenital cancer

· Gastrointestinal cancer

· Immuno-oncology

Recent Publications

•  An overview of hormonal directed pharmacotherapy for the treatment of prostate cancer, Expert Opinion on Pharmacotherapy, 24:16, 1765-1774, DOI: 10.1080/14656566.2023.2244415 Maria Mitsogianni, Athanasios Papatsoris, Vanessa-Meletia Bala, Hussein Issa, Mohammad Moussa & Iraklis Mitsogiannis (2023)

• The potential role of the combined PARP-1 and VEGF inhibition in severe SARS-CoV-2 (COVID-19) infection. The Journal of Infection in Developing Countries 2022-01-31 | Journal article DOI: 10.3855/jidc.15386 Dimitra Ioanna Lampropoulou; Vanessa Meletia Bala; Eleni Zerva; Evangelia Pliakou; Dimitrios Filippou; Maria Gazouli; Gerasimos Aravantinos

• Mediastinal and hilar sarcoid-like reaction in a patient treated with dabrafenib and trametinib for metastatic melanoma: A case report and review of the literature. Mol Clin Oncol. 2022 May;16(5):99. doi: 10.3892/mco.2022.2532. Bala VM, Mitsogianni M, Laschos K, Pliakou E, Lazaridi E, Lampropoulou DI, Aravantinos G.